Prevalence and Associations of VTE in Patients With Newly Diagnosed Lung Cancer

Zhang, Yuhui; Yang, Yuanhua; Chen, Wenhui; Guo, Lijuan; Liang, Lirong; Zhai, Zhenguo; Wang, Chen

doi:10.1378/chest.13-2379

Cited by 75 publications

(82 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The incidence of VTE in this study is similar to what has been reported in the literature [5,21]. Although this incidence is not as high as in other solid malignancies (e.g.…”

Section: Discussionsupporting

confidence: 90%

Early Venous Thromboembolic Events Are Associated With Worse Prognosis in Patients With Lung Cancer

Kourelis

Wysokinska

Wang

et al. 2014

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…The incidence of VTE in this study is similar to what has been reported in the literature [5,21]. Although this incidence is not as high as in other solid malignancies (e.g.…”

Section: Discussionsupporting

confidence: 90%

Early Venous Thromboembolic Events Are Associated With Worse Prognosis in Patients With Lung Cancer

Kourelis

Wysokinska

Wang

et al. 2014

International Journal of Radiation Oncology*Biology*Physics

View full text Add to dashboard Cite

“…The incidence of VTE in this study is similar to what has been reported in the literature [5,21]. Although this incidence is not as high as in other solid malignancies (e.g.…”

Section: Discussionsupporting

confidence: 90%

Early venous thromboembolic events are associated with worse prognosis in patients with lung cancer

et al. 2014

View full text Add to dashboard Cite

Objectives Venous thromboembolic events (VTE) are a leading cause of death in cancer patients. We hypothesized that early VTE (EVTE, within 3 months of diagnosis) in patients with lung cancer (LC) are associated with worse overall survival (OS). Materials and methods We identified 727 patients with LC between 1998 and 2011. Late VTE (LVTE) were defined as VTE occurring after 3 months from LC diagnosis. Advance disease (AD) was defined as patients with Stage IV non-small cell lung cancer (NSCLC) or extensive stage small cell lung cancer (SCLC), and non-advanced disease (non-AD) was defined as ≤ Stage III NSCLC or limited stage SCLC. Results Out of 727 patients included in our review, 617 patients had NSCLC (85%), 94 (13%) SCLC, and 16 (2%) low grade neuroendocrine tumors. Ninety five patients (13%) experienced VTE, 44 (6%) experienced an EVTE and 49 (7%) had a LVTE. Patients with an EVTE had worse OS when compared to all other patients (medians 4 vs. 17 months, p < 0.0001). EVTE were associated with worse OS in patients with non-AD (medians 12 vs. 42 months, p = 0.01) and AD (medians 4 vs. 6 months, p = 0.02). When considering patients with NSCLC only, in a multivariate model that included age, stage, performance status > 2, administration of chemotherapy and Charlson comorbidity index, EVTE were an independent predictor of increased mortality (HR 2.4; 95% CI 1.6–3.3). Conclusions EVTE are associated with worse OS, irrespective of stage of the disease. Our findings underscore the need for an efficient preventive strategy for VTE among patients with lung cancer.

show abstract

“…In a study of patients with nonsmall-cell lung cancer (NSCLC), patients younger than 45 years had an approximately three-fold higher risk of VTE than patients older than 75 years [17]. Consistent with these findings Zhang et al's study showed a significant association between young age and the risk of pulmonary embolism in lung cancer patients [9 ]. Although increasing age is an established VTE risk factor in the general population, it might contribute to a lesser extent to the occurrence of VTE in lung cancer.…”

Section: Patient-related Risk Factorsmentioning

confidence: 77%